Busy Sanofi takes a pass on one of Al­ny­lam’s rare dis­ease drugs, FDA of­fers ‘break­through’ sta­tus for PhI­II

A cou­ple of months af­ter Sanofi $SNY and Al­ny­lam $AL­NY re­tooled their RNAi col­lab­o­ra­tion so that the French phar­ma gi­ant could con­cen­trate on their he­mo­phil­ia ther­a­py while giv­ing up rights to the biotech’s patisir­an, the two part­ners are al­so go­ing their sep­a­rate ways on a late-stage drug for rare cas­es of pri­ma­ry hy­per­ox­aluria type 1.

Sanofi is tak­ing a pass on an op­tion for lumasir­an (ALN-GO1), leav­ing Al­ny­lam CEO John Maraganore to take the drug in­to Phase III with a brand new break­through drug des­ig­na­tion from the FDA to speed things along.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER